David Hardy, MD

CRS:

JHU

Role:

Investigators

Dr. W. David Hardy formerly served as Senior Director of Evidence-based Practices, ACTG clinical research site (CRS) leader, MACS co-investigator and HIV/primary care provider at Whitman-Walker Health in Washington, D.C. He holds an Adjunct Professor of[HD1]  Medicine appointment at Johns Hopkins University School of Medicine in Baltimore.  He previously served as Director, Division of Infectious Diseases at Cedars-Sinai Medical Center and Professor of Medicine at the David Geffen School of Medicine at UCLA. Just prior to joining Whitman-Walker, Dr Hardy was CMO for Calimmune, a California-based and funded (CIRM), translational science biotech investigating gene-modified CD4+ T cells and hematopoietic stem cells as a potential cure for HIV infection.

He received his medical degree from Baylor College of Medicine, Houston, TX and completed his residency in internal medicine at Harbor-UCLA Medical Center in Torrance, California. Early in the AIDS epidemic (1984-86), he completed a clinical fellowship in infectious diseases/immunology and clinical research at the UCLA School of Medicine under the direction of Dr Michael Gottlieb. Later he also completed a post-doctoral fellowship in molecular retrovirology with Irvin Chen, PhD at the David Geffen School of Medicine at UCLA focusing on development of retroviral vector delivery of gene therapy and vaccine applications.

Dr. Hardy has cared for persons with HIV infection since 1982 and conducted research on the disease since 1984. Initially, he focused on treatment and prevention of opportunistic infections and currently on antiretroviral agents, immunotherapies and hepatitis treatments as well as retroviral vector research and gene therapy.  Dr. Hardy currently serves on the Board of Directors of the American Academy of HIV Medicine and chair of the Education Committee. He served as editor-in-chief of the American Academy of HIV Medicine (AAHIVM) comprehensive textbook, Fundamentals of HIV Medicine for the HIV Specialist published in 2012 and 2016. Dr Hardy also served on the Board of Directors of the HIV Medicine Association (HIVMA) as an infectious diseases representative from 2011-2014.

  • CRS Leader At-Large, ACTG Performance Evaluation Committee (PEC)
    (Mar 2016-Nov 2018)
  • Co-chair, ACTG 5370 (2017)
  • Member, Viral Eradication and HIV Reservoirs (Cure) Transformative Science Group

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More

A5273: Multicenter Study of Options for Second-Line...

The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...

Read More

A5279, Phase III Clinical Trial of Ultra-Short-Course...

This study will enroll HIV-infected people who do not have evidence of active TB but who are at high risk of developing active...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More